Immunotherapy: Present and future directions

Debebe Theodros, Eric W. Sankey, C. Rory Goodwin, Michael Lim

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The role of immunotherapy in oncology has rapidly expanded over the past century. The old paradigm posited the brain to be an "immune-privileged" location, as the tumor microenvironment has been shown to be highly immunosuppressive in nature. However, more recent observations have paved the way for the use of immunotherapy in neurooncology. Immuno-modulation represents a promising treatment paradigm in conjunction with standard of care therapy that has the potential to greatly improve morbidity and mortality in patients with high-grade gliomas. Various targeted treatment modalities have arisen and include surface-directed immunotherapies, adoptive lymphocyte transfer, vaccines, and immune checkpoint blockade. Each treatment modality seeks to take advantage of tumor biology. Surfacedirected immunotherapies exploit over-expressed cell surface receptors on tumor cells. Adoptive lymphocyte transfer employs cytotoxic antigen-specific T-cells against tumors. Vaccines enhance the host antigen-specific anti-tumor immune response with minimal side effects. Finally, immune checkpoint blockade seeks to reverse tumor-mediated T-cell exhaustion and restore the host anti-tumor immune response. Each of these therapies has demonstrated successful anti-tumor immune-mediated responses in pre-clinical and clinical models, alike. Despite such success, multiple challenges to implementation and optimization of immunotherapy remain. For instance, small cohorts and molecularly unique tumors preclude broader generalizations. Additionally, dynamic tumor biology once susceptible to one immunotherapy modality may become resistant to the same treatment approach over time. However, immunotherapy has demonstrated a proven role established by myriad pre-clinical and clinical studies. Future work will investigate the promising role of combining immunotherapy with the current standard of care in the hopes of improving morbidity and mortality.

Original languageEnglish (US)
Title of host publicationGlioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome
PublisherNova Science Publishers, Inc.
Pages135-148
Number of pages14
ISBN (Print)9781634832892, 9781634832731
StatePublished - Jul 1 2015

Fingerprint

Immunotherapy
Neoplasms
Adoptive Transfer
Standard of Care
Therapeutics
Vaccines
Lymphocytes
Morbidity
T-Lymphocytes
Direction compound
Antigens
Tumor Microenvironment
Mortality
Cell Surface Receptors
Immunosuppressive Agents
Glioma
Brain

Keywords

  • Chimeric antigen receptors (CARs)
  • EGFR
  • IL-13Ra2
  • Immuno-modulation
  • Immuno-therapy
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Theodros, D., Sankey, E. W., Goodwin, C. R., & Lim, M. (2015). Immunotherapy: Present and future directions. In Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome (pp. 135-148). Nova Science Publishers, Inc..

Immunotherapy : Present and future directions. / Theodros, Debebe; Sankey, Eric W.; Goodwin, C. Rory; Lim, Michael.

Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc., 2015. p. 135-148.

Research output: Chapter in Book/Report/Conference proceedingChapter

Theodros, D, Sankey, EW, Goodwin, CR & Lim, M 2015, Immunotherapy: Present and future directions. in Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc., pp. 135-148.
Theodros D, Sankey EW, Goodwin CR, Lim M. Immunotherapy: Present and future directions. In Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc. 2015. p. 135-148
Theodros, Debebe ; Sankey, Eric W. ; Goodwin, C. Rory ; Lim, Michael. / Immunotherapy : Present and future directions. Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc., 2015. pp. 135-148
@inbook{cd24be28595447498ba0f2496e148052,
title = "Immunotherapy: Present and future directions",
abstract = "The role of immunotherapy in oncology has rapidly expanded over the past century. The old paradigm posited the brain to be an {"}immune-privileged{"} location, as the tumor microenvironment has been shown to be highly immunosuppressive in nature. However, more recent observations have paved the way for the use of immunotherapy in neurooncology. Immuno-modulation represents a promising treatment paradigm in conjunction with standard of care therapy that has the potential to greatly improve morbidity and mortality in patients with high-grade gliomas. Various targeted treatment modalities have arisen and include surface-directed immunotherapies, adoptive lymphocyte transfer, vaccines, and immune checkpoint blockade. Each treatment modality seeks to take advantage of tumor biology. Surfacedirected immunotherapies exploit over-expressed cell surface receptors on tumor cells. Adoptive lymphocyte transfer employs cytotoxic antigen-specific T-cells against tumors. Vaccines enhance the host antigen-specific anti-tumor immune response with minimal side effects. Finally, immune checkpoint blockade seeks to reverse tumor-mediated T-cell exhaustion and restore the host anti-tumor immune response. Each of these therapies has demonstrated successful anti-tumor immune-mediated responses in pre-clinical and clinical models, alike. Despite such success, multiple challenges to implementation and optimization of immunotherapy remain. For instance, small cohorts and molecularly unique tumors preclude broader generalizations. Additionally, dynamic tumor biology once susceptible to one immunotherapy modality may become resistant to the same treatment approach over time. However, immunotherapy has demonstrated a proven role established by myriad pre-clinical and clinical studies. Future work will investigate the promising role of combining immunotherapy with the current standard of care in the hopes of improving morbidity and mortality.",
keywords = "Chimeric antigen receptors (CARs), EGFR, IL-13Ra2, Immuno-modulation, Immuno-therapy, Immunotherapy, Vaccine",
author = "Debebe Theodros and Sankey, {Eric W.} and Goodwin, {C. Rory} and Michael Lim",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
isbn = "9781634832892",
pages = "135--148",
booktitle = "Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Immunotherapy

T2 - Present and future directions

AU - Theodros, Debebe

AU - Sankey, Eric W.

AU - Goodwin, C. Rory

AU - Lim, Michael

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The role of immunotherapy in oncology has rapidly expanded over the past century. The old paradigm posited the brain to be an "immune-privileged" location, as the tumor microenvironment has been shown to be highly immunosuppressive in nature. However, more recent observations have paved the way for the use of immunotherapy in neurooncology. Immuno-modulation represents a promising treatment paradigm in conjunction with standard of care therapy that has the potential to greatly improve morbidity and mortality in patients with high-grade gliomas. Various targeted treatment modalities have arisen and include surface-directed immunotherapies, adoptive lymphocyte transfer, vaccines, and immune checkpoint blockade. Each treatment modality seeks to take advantage of tumor biology. Surfacedirected immunotherapies exploit over-expressed cell surface receptors on tumor cells. Adoptive lymphocyte transfer employs cytotoxic antigen-specific T-cells against tumors. Vaccines enhance the host antigen-specific anti-tumor immune response with minimal side effects. Finally, immune checkpoint blockade seeks to reverse tumor-mediated T-cell exhaustion and restore the host anti-tumor immune response. Each of these therapies has demonstrated successful anti-tumor immune-mediated responses in pre-clinical and clinical models, alike. Despite such success, multiple challenges to implementation and optimization of immunotherapy remain. For instance, small cohorts and molecularly unique tumors preclude broader generalizations. Additionally, dynamic tumor biology once susceptible to one immunotherapy modality may become resistant to the same treatment approach over time. However, immunotherapy has demonstrated a proven role established by myriad pre-clinical and clinical studies. Future work will investigate the promising role of combining immunotherapy with the current standard of care in the hopes of improving morbidity and mortality.

AB - The role of immunotherapy in oncology has rapidly expanded over the past century. The old paradigm posited the brain to be an "immune-privileged" location, as the tumor microenvironment has been shown to be highly immunosuppressive in nature. However, more recent observations have paved the way for the use of immunotherapy in neurooncology. Immuno-modulation represents a promising treatment paradigm in conjunction with standard of care therapy that has the potential to greatly improve morbidity and mortality in patients with high-grade gliomas. Various targeted treatment modalities have arisen and include surface-directed immunotherapies, adoptive lymphocyte transfer, vaccines, and immune checkpoint blockade. Each treatment modality seeks to take advantage of tumor biology. Surfacedirected immunotherapies exploit over-expressed cell surface receptors on tumor cells. Adoptive lymphocyte transfer employs cytotoxic antigen-specific T-cells against tumors. Vaccines enhance the host antigen-specific anti-tumor immune response with minimal side effects. Finally, immune checkpoint blockade seeks to reverse tumor-mediated T-cell exhaustion and restore the host anti-tumor immune response. Each of these therapies has demonstrated successful anti-tumor immune-mediated responses in pre-clinical and clinical models, alike. Despite such success, multiple challenges to implementation and optimization of immunotherapy remain. For instance, small cohorts and molecularly unique tumors preclude broader generalizations. Additionally, dynamic tumor biology once susceptible to one immunotherapy modality may become resistant to the same treatment approach over time. However, immunotherapy has demonstrated a proven role established by myriad pre-clinical and clinical studies. Future work will investigate the promising role of combining immunotherapy with the current standard of care in the hopes of improving morbidity and mortality.

KW - Chimeric antigen receptors (CARs)

KW - EGFR

KW - IL-13Ra2

KW - Immuno-modulation

KW - Immuno-therapy

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84957940283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957940283&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84957940283

SN - 9781634832892

SN - 9781634832731

SP - 135

EP - 148

BT - Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome

PB - Nova Science Publishers, Inc.

ER -